Article Text

Download PDFPDF

Original article
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
  1. David G Warnock1,
  2. Christie P Thomas2,
  3. Bojan Vujkovac3,
  4. Ruth C Campbell4,
  5. Joel Charrow5,
  6. Dawn A Laney6,
  7. Leslie L Jackson1,
  8. William R Wilcox6,
  9. Christoph Wanner7
  1. 1Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
  2. 2Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
  3. 3General Hospital, Slovenj Gradec, Slovenia
  4. 4Department of Medicine, Medical University of South Caroline, Charleston, South Carolina, USA
  5. 5Departments of Pediatrics-Genetics, Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA
  6. 6Department of Human Genetics, Emory University, Atlanta, Georgia, USA
  7. 7Department of Nephrology, University Klinik Würzburg, Würzburg, Germany
  1. Correspondence to Dr David G Warnock, Room 614 ZRB, UAB, 1720 2nd Avenue South, Birmingham, AL 34294-0007, USA; dwarnock{at}

Statistics from

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.